Liraglutide vs Pemvidutide

Liraglutide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, obesity, and cardiovascular risk reduction, and is sold under the brand names Saxenda and Victoza. Pemvidutide is a newer GLP-1 and glucagon dual-receptor drug still in development, with no FDA approvals yet and no branded products on the market.

AI summary of the sources below.